Lebrikizumab

Lebrikizumab is a monoclonal antibody designed for the treatment of asthma and other inflammatory diseases. It is developed by Roche, a Swiss multinational healthcare company.

Mechanism of Action

Lebrikizumab works by targeting interleukin-13 (IL-13), a cytokine that plays a key role in the inflammatory response in asthma. By binding to IL-13, lebrikizumab prevents it from interacting with its receptor, thereby reducing inflammation and improving lung function.

Clinical Trials

Lebrikizumab has undergone several clinical trials to evaluate its safety and efficacy. In Phase II trials, it demonstrated a significant improvement in lung function in patients with moderate to severe asthma. Phase III trials are currently underway.

Side Effects

Common side effects of lebrikizumab include headache, nasopharyngitis (common cold), and upper respiratory tract infection. Serious side effects may include allergic reactions and infections.

Regulatory Status

As of 2021, lebrikizumab is not yet approved by the Food and Drug Administration (FDA) or any other regulatory authority. However, it has been granted Breakthrough Therapy designation by the FDA for the treatment of severe asthma.

See Also

• Monoclonal antibodies
• Interleukin-13
• Clinical trials
• Food and Drug Administration

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

‎